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Case Report

Case report

SpaceOAR to improve dosimetric outcomes for
monotherapy high-dose-rate prostate implantation
in a patient with ulcerative colitis
Michael Trager, MS, Benjamin Greenberger, MD, Amy S Harrison, PhD, James Keller, PhD, Robert B Den, MD
Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

Abstract
High-dose-rate (HDR) brachytherapy is an attractive option for patients receiving definitive radiation therapy for
prostate cancer with decreased overall dose to the pelvis. However, ulcerative colitis increases rectal toxicity risk and
may be a contraindication. A synthetic hydrogel, SpaceOAR (Augmentix Inc., Waltham, MA, USA), can facilitate the
use of HDR brachytherapy for patients where rectal toxicity is a limiting factor.
SpaceOAR gel (13.19 cc) was utilized in a monotherapy HDR prostate treatment with Ir-192 under transrectal ultrasound guidance, with the intention of decreasing rectal dose. SpaceOAR gel was inserted transperineally into the
patient 18 days prior to the procedure.
The HDR brachytherapy procedure was tolerated without incident. All planning constraints were met, and the
following dosimetry was achieved: Prostate – V100% = 97.3%, V150% = 35%, V200% = 14.5%; Urethra – V118% = 0%; Rectum – D2 cc = 51.6%, V75% = 0 cc. The rectum-catheter spacing was on average between 6-8 mm. Average spacing for
our 10 most recent patients without SpaceOAR was 3 mm. SpaceOAR did not hinder or distort ultrasound imaging or
increase treatment time.
SpaceOAR successfully increases catheter-rectal wall spacing and decreases rectal dose due to improved planning
capabilities, while decreasing the likelihood of rectal perforation. One application of this tool is presented to mitigate
potential toxicities associated with ulcerative colitis. At five months, one week, and one day follow-up, the patient
reported no bowel issues following HDR brachytherapy.
J Contemp Brachytherapy 2018; 10, 6: 577–582
DOI: https://doi.org/10.5114/jcb.2018.81001
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Purpose
Radiation therapy (RT) for prostate cancer is
a well-established and effective treatment technique with
various treatment options backed by randomized trials
and single-institutional studies [1]. Although radiation
modalities such as external beam radiotherapy (EBRT)
and brachytherapy are effective in the management of
prostate cancer, a concern regarding short and late toxicity plays a pivotal role in modality selection, dose, and
duration of therapy, motivating recent advances in technique of delivery.
The ProtecT trial concluded no significant difference among the prostate-cancer-specific mortality rates
in observation versus surgery or RT; however, they did
note increased genitourinary (GU) toxicities and erectile dysfunction following surgery as well as increased
gastrointestinal (GI) toxicities from RT [2]. Rectal toxicities are a limiting factor in RT for prostate cancer due
to a high rectal dose attributed to the proximity of the

prostate and rectum, with significantly higher toxicity
correlated to dose to the inferior rectum [3,4,5]. In some
patients, the degree of rectal toxicity may be a key factor
governing treatment selection. Willet et al. [6] reported
increased rectal toxicity associated with RT and irritable
bowel disease (IBD), specifically ulcerative colitis (UC), as
well as severe rectal toxicities in patients with IBD undergoing abdominopelvic irradiation. Furthermore, acute
GI toxicity of grade 2 or higher is exacerbated in patients
undergoing concomitant medical therapy for IBD [7]. Advances in modern RT have demonstrated a trend toward
improved toxicity profiles from treatment in high-risk
groups such as patients with IBD [8,9].
Although advances in image-guided radiation therapy (IGRT) and treatment technique may facilitate the
use of RT in patients with a concern for rectal toxicity,
modern trends in EBRT and brachytherapy application
towards dose escalation and hypofractionation contribute to renewed concern regarding sparing rectal dose.
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Several reports and phase III clinical trials incorporating
patients of varied risk stratification have demonstrated
improved biochemical control with modern dose escalated EBRT [10,11,12,13,14,15]. Given favorable therapeutic
ratio and logistic advantages, moderate and extreme hypofractionation have been a focus of recent randomized
trials of the past decade [16,17,18,19,20]. Although not
conclusively shown in the majority of hypofractionation
trials to date, there have been reports of increased rectal
toxicity associated with larger dose per fraction [21].
Brachytherapy remains a curative alternative to radical prostatectomy or EBRT for early stage disease, with
no significant differences in treatment results but lower
rates of urinary incontinence and increased preservation of sexual function [22]. Trends in brachytherapy
have similarly explored dose escalation and completion
of treatment within fewer sessions with high-dose-rate
(HDR) techniques [23]. Although late grade 3 rectal toxicity is rare following definitive upfront brachytherapy,
well below 5% in most series, dosimetric rectal outcome
has been shown to be overall improved with HDR compared to EBRT [24]. In instances of salvage brachytherapy following biochemical failure post-EBRT, a higher
incidence of grade 2/3 rectal toxicity has been reported
in low-dose-rate (LDR) and HDR series [25]. When considering upfront treatments in the recent ASCENDE-RT
trial, addition of brachytherapy boost to 78 Gy EBRT
demonstrated an increase in grade 3 rectal toxicity from
3.2% to 8.1% [26]. In patients receiving HDR monotherapy (19 Gy in single fraction), Krauss et al. [27] reported grade 1/2 acute and chronic GI toxicities in 12%/0%
and 12.1%/1.7% of patients, respectively, and Prada et al.
[28] reported acute grade 1 GI toxicities up to 7%, with
no grade 2 acute or grade 1/2 chronic GI toxicities. It is
likely that further techniques designed to improve rectal
dosimetry in the context of brachytherapy will continue
to lead to less acute and late toxicity.
Displacement of normal tissue has long been explored
as a viable strategy to improve dosimetry to organs at
risk (OARs) [29]. For prostate RT, a novel technique for
sparing high-dose to the anterior rectal wall is the use of
a synthetic gel injection into the space between the prostate and rectum [30,31,32,33,34]. The feasibility and effects
on toxicity of these rectal displacement gels has been reported by various investigators. Prada et al. [35] reported
the successful use of a rectal wall displacement technique
in single fraction HDR brachytherapy as monotherapy,
with no additional toxicities and the same biochemical
control at 32 months. Strom et al. [36] reported successful
implementation of a polyethylene glycol (PEG) hydrogel
for HDR brachytherapy plus or minus intensity-modulated radiation therapy (IMRT), with significantly increased
prostate-rectal distance and significantly decreased mean
rectal doses. Yeh et al. [37] similarly looked at a PEG hydrogel for HDR brachytherapy plus or minus IMRT and
also reported increased prostate-rectal distance as well as
low acute and chronic rectal toxicities despite aggressive
dose escalation. SpaceOAR (Augmentix Inc., Waltham,
MA, USA) is an FDA-approved gel, evaluated as having
a benefit in reducing rectal dose, toxicity, and quality of
life declines by a phase III trial with a median follow-up

period of 3 years [33,38,39]. At our clinic, SpaceOAR is
typically injected under ultrasound guidance at the conclusion of an HDR prostate procedure performed prior
to external beam hypofractionated prostate RT, while patients are under general anesthesia. The use of SpaceOAR
for these patients has effectively reduced high-dose to the
rectum consistent with that shown in the phase III trial
previously mentioned. Here, we report the potential benefit of injecting SpaceOAR prior to a monotherapy HDR
prostate implantation, with the primary goal of mitigating GI toxicity due to UC.

Case presentation
A 73-year-old patient initially presented with an elevated prostate-specific antigen (PSA) of 9.94 ng/ml. He
received a prostate biopsy, which confirmed intermediate-risk adenocarcinoma of the prostate, GG 2 stage IIB
(cT2bN0M0, Gleason score of 3 + 4 = 7 in 3/12 cores).
Brachytherapy with 19 Gy in a single fraction with SpaceOAR was chosen as monotherapy for this patient instead of EBRT due the patient’s UC and concomitant
medication use of azathioprine.
The SpaceOAR gel implantation was performed 18
days prior to the HDR procedure in sterile dorsal lithotomy position with an ultrasound stepper and transrectal
ultrasound (TRUS). This timing was a result of logistical
and scheduling considerations between the time of injection and the HDR procedure. A waiting period of at least
three days before HDR is necessary to allow local gas to
adequately resolve, restoring visualization of the prostate
gland, which is immediately lost following the injection.
Using 1% lidocaine, the perineum was numbed, followed
by the prostatic neurovascular bundles via TRUS guidance. The SpaceOAR needle was then advanced to the
mid prostate at midline, and a 1 cc injection of saline
was used to identify the correct position posterior to the
prostate and completely anterior to the rectum. SpaceOAR was then attached and injected to completion. At Jefferson hospital, the average SpaceOAR volume injected
into patients receiving hypofractionated EBRT following
HDR prostate treatment is 10.5 cc (range, 6.88-14.08 cc) as
seen on magnetic resonance imaging (MRI). The SpaceOAR volume used in this case as seen on MRI was 13.19 cc
and unintentionally asymmetrically displaced slightly to
the patient’s left during injection. Injection volume varies
with application [30,34].
For the monotherapy HDR prostate brachytherapy
procedure, the patient was in dorsal lithotomy position
and induced under general anesthesia. A Foley catheter was inserted. Rectal preparation was verified, and
perineum was prepped with betadine. A TRUS probe
with a brachytherapy ultrasound stepper was inserted
into the rectum, and the prostate was visualized and
measured to be 39 cc. Using a template-based approach,
17 catheters were inserted from anterior to posterior prostate in a modified periphery loading technique. Catheter
positions were verified in the transverse and sagittal positions and depths were confirmed. The target volume,
normal tissues (rectum and urethra), and SpaceOAR
were contoured by the attending physician, and real-time
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Fig. 1. Axial slices from an ultrasound image taken before (left; four anchor needles only) and after (right) complete needle
implantation during an HDR brachytherapy prostate procedure post-SpaceOAR injection. The SpaceOAR gel (surrounded by
red arrows in right image) and implanted needles (bright spots) are clearly visualized

inverse planning (Nucletron Oncentra® Prostate v.4.2.2.4)
was performed by physics. All constraints were met as
follows: Prostate – V100% > 95%, V150% < 35%, V200% < 12%;
Urethra – Dpoint max < 120%, D10% < 115%; Rectum –
Dpoint max < 90%, V80% < 0.2 cc [27]. After plan checks by
the physician and physicists, catheters were connected to
the microSelectron® v2 Ir-192 HDR afterloader (Nucletron,
The Netherlands) and the treatment was delivered via
Nucletron Oncentra® TCS. After delivery, catheters were
removed, perineum was cleaned, and the patient was extubated. The procedure was tolerated without incident.

The dosimetric benefit of increasing prostate and rectal separation is the primary objective of using the SpaceOAR gel during HDR prostate implantations. This can
be seen in the craniocaudal direction on the sagittal image
(Figure 2) and anteroposterior direction in the axial images (Figure 1 and Figure 3). The average distance between
the closest needle and the rectal wall in the past ten HDR
prostate procedures at our institution was 3 mm (median,
2.9 mm; max, 6.3 mm; min, 0.4 mm). Utilizing SpaceOAR, the distance between the closest needle and the rectal
wall lacking SpaceOAR averaged 6 mm, and the distance

Discussion
The SpaceOAR is placed between the ultrasound
probe and needles, thus it was hypothesized to decrease
visualization of the needles due to the potential for various distorting effects seen in ultrasound such as reflection,
refraction, and shadowing that occur at tissue interfaces.
Consistent with vendor literature, there was no visual hindrance or distortion of the needles due to the gel and the
gel was clearly visible on the ultrasound image (Figure 1).
After analysis, this makes sense since the SpaceOAR gel
had an average Hounsfield Unit (HU) value of 7 based on
the average SpaceOAR HUs from the CT scans of patients
previously treated at our institution, which is very close to
water (HU = 0) and should therefore have a similar density and acoustic impedance resulting in minimal ultrasound distortion. Maintaining satisfactory image quality
validates the feasibility of utilizing SpaceOAR prior to
HDR as a rectal protector for patients with UC. It is interesting to note, however, that there is a large discrepancy
in SpaceOAR volume between ultrasound (5.622 cc) and
MRI (13.19 cc). Part of this discrepancy arises from the
superior resolution and quality of the MRI. Discrepancies
also arise from the displacement of anatomy due to the
rectal ultrasound probe. The large SpaceOAR volume discrepancy between ultrasound and MRI has no impact on
patient care; however, is important to consider.

Prostate
Urethra
Rectum
SpaceOAR

Fig. 2. Sagittal slice from an ultrasound image after complete needle implantation during an HDR brachytherapy
prostate procedure post-SpaceOAR injection with overlaid contours. Please note that the poor image quality results from this image’s reconstruction from an axially acquired ultrasound and that the contours were generated
in the axial view where image quality is adequate. This
image is meant for visualization of the gel’s craniocaudal
displacement of the prostate
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Fig. 3. Isodose distribution and contours from the HDR
brachytherapy prostate implant overlaid on the ultrasound image

between a needle within the region of the SpaceOAR
and rectal wall was greater than 8 mm. In regions of no
SpaceOAR, its contralateral presence increased the prostate-rectum spacing. This increased separation and shift
in isodose lines is beneficial due to the large dose gradient
obtained with an Ir-192 source (Figure 3). In a phase I study
done at our institution to assess the safety, tolerability,
and preliminary efficacy of HDR brachytherapy in combination with hypofractionated VMAT in intermediate-risk
prostate cancer, the following median dosimetry was reported for 22 patient plans [40]: Prostate – V100% = 96.3%,
V150% = 39.4%, V200% = 15.3%; Urethra – V118% = 1.39%,
D2cc = 71.7%; Rectum – V75% = 1.3 cc. This case achieved:
Prostate – V100% = 97.3%, V150% = 35%, V200% = 14.5%;
Urethra – V118% = 0%; Rectum – D2cc = 51.6%, V75% = 0 cc
(Figure 4).
Using a more conservative α/β of 3 Gy for rectum,
max equivalent dose at 2 Gy per fraction (EQD2) to 2 cc of
rectum was 25.1 Gy, in accordance with GEC-ESTRO recommendations to include a D2cc to rectum less than 75 Gy
by EQD2 [41,42]. SpaceOAR resulted in better dosimetry
for all critical dosimetric indices as reported in our phase
I trial [40]. QUANTEC guidelines suggest a conservative
DVH constraint set for the rectum of V50Gy < 50%, V60Gy <
35%, V65Gy < 25%, V70Gy < 20%, and V75Gy < 15% [3]. As our
D2cc rectum was 25.1 Gy after EQD2 conversion using an
α/β of 3 for late effects, these dose constraints were easily
met. This is likely attributed to an ideal implant in addition to increased prostate-rectum spacing, which allowed
the optimizer to effectively utilize posterior catheters.
SpaceOAR did not impede standard procedure times,
which is important as the patient is under general anesthesia and complication probabilities increase with increased duration of the procedure. The time from patient
intubation to HDR initiation was 211 minutes, which is
on par with our average HDR prostate procedure time
of 203 minutes taken from eight previous procedures.
However, there are many variables contributing to procedure time, which makes it difficult to assess and compare
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Fig. 4. Dose-volume histogram from the HDR brachytherapy prostate procedure

actual times on a case-by-case basis. Additional patient
safety factors created by SpaceOAR are buffer space between needle placement and the rectum, which decreases
the probability of rectal perforation. Mariados et al. [30]
report no device-related adverse events or rectal perforations during the use of the spacer and discuss ease of use
for applying the spacer with 98.7% placement success.

Conclusions
SpaceOAR successfully increased catheter-rectal wall
spacing and decreased rectal dose due to improved planning capabilities, while decreasing the likelihood of rectal
perforation. Although difficult to directly conclude given
the lack of prospective randomized series, incorporating
techniques to increase prostate-rectal wall separation may
be of particular benefit to high-risk patients. This technique
is prominent in EBRT and may be of interest in brachytherapy incorporating HDR hypofractionated treatment. This
particular case report demonstrates one application of this
concept in a patient with UC with favorable dosimetric
outcome. The patient tolerated the SpaceOAR injection
and HDR brachytherapy procedures well. At five months,
one week, and one day follow-up, the patient reported no
bowel issues following HDR brachytherapy.
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